Company Overview
Iterum Therapeutics plc operates as a pharmaceutical company dedicated to the development and commercialization of treatments specifically targeting drug-resistant bacterial infections across markets in Ireland, Bermuda, and the United States. The company functions within the Healthcare sector, specifically classified under the Biotechnology industry, which implies a focus on early-stage research and high-risk product development rather than established consumer goods. This biotechnology entity maintains a minimal operational scale, employing only 9 individuals to support its R&D and commercialization efforts. The company's market capitalization stands at $1.90M with an annual revenue of $390,000, figures that indicate an extremely early-stage micro-cap status typical of firms prioritizing pipeline advancement over current profitability. These valuation metrics suggest the company is currently in a pre-commercial or early-commercialization phase where the primary value driver is the potential of its product portfolio, particularly its oral penem antibiotic, ORLYNVAH, designed for uncomplicated urinary tract infections caused by Es, rather than existing cash flows or market dominance.
Financial Health
The company reported a revenue of $390,000 over the trailing twelve months, while simultaneously posting a net income of $-26,961,000 and an EBITDA of $-19,324,000. The substantial gap between the minimal revenue of $390,000 and the significant net loss of $-26,961,000 reveals a cost structure dominated by heavy research and development expenditures that far exceed current sales generation. Free cash flow stands at $-13,851,125, indicating that the company is burning cash rapidly to fund operations and development, which severely limits its current financial flexibility and necessitates external capital raising to sustain activities. Profitability analysis shows a gross margin of 29.7%, reflecting some efficiency in the cost of goods sold relative to revenue, but an operating margin of -1982.3% and a profit margin of 0.0% highlight extreme operational inefficiencies driven by high overhead costs relative to sales. On the balance sheet, the company holds $11.00M in cash against $33.73M in debt, creating a net debt position that suggests a highly leveraged state despite the lack of a calculable debt-to-equity ratio due to negative equity implications. The current ratio of 2.13 indicates that the company possesses sufficient liquid assets to cover its short-term liabilities more than twice over, suggesting adequate short-term liquidity management despite the long-term debt burden. Return on Equity is listed as N/A due to the negative equity position, while a return on assets of -53.3% reveals that management is generating significant negative returns on the capital base, indicating a current inability to effectively deploy assets for profit generation.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of positive net income, while the forward P/E is calculated at -0.05, implying that the market currently prices in future earnings recovery rather than historical performance. The price-to-book ratio is -0.24, a metric that indicates the company's market value is trading below its book value, often seen in distressed or pre-profit biotechnology firms where assets are not yet fully monetized. Alternative valuation metrics show a price-to-sales ratio of 4.86 and an EV/EBITDA of -1.27, suggesting that investors are valuing the company primarily on its revenue potential and asset backing rather than earnings multiples, which is standard for development-stage companies. The stock has exhibited extreme volatility within a 52-week range bounded by a high of $1.50 and a low of $0.03, with the current trading price situated significantly below the 52-week high of $1.50. The beta value of 3.01 indicates that the stock's price volatility is three times greater than the broader market, meaning price swings are amplified relative to general market movements.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the early stage of the business where historical comparison is not yet applicable. Since the company reports a net loss and zero profit margin, it does not pay dividends, resulting in a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests all available earnings, including cash reserves, directly back into research, development, and commercialization efforts rather than distributing returns to shareholders. The overall growth and income profile is characterized by a complete absence of current income generation and undefined growth rates, as the firm remains in a phase where capital preservation and pipeline progression take precedence over financial returns.